Loxo Oncology
Eli Lilly to buy Loxo Oncology in deal worth $8 billion
January 7, 2019Manufacturing and Production Cancer, Eli Lilly, Loxo Oncology, gene therapy, personalised medicine
US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in …
FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi
November 27, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma
The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …
New targeted therapy promises strong response rate across 17 cancer types
June 5, 2017Research and Development, Sales and Marketing ASCO, Cancer, Loxo Oncology, oncology
Loxo Oncology’s lead therapy larotrectinib made a big impact at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
September 25, 2026
One in three UK women with migraine say symptoms taken less seriously
September 24, 2026
Report highlights scope to expand day surgery
September 23, 2026
Sygnature formalises drug discovery collaboration with X-Chem
September 22, 2026
Codis appoints Steven Facer as chief commercial officer
September 21, 2026
